# Exploring the Influence of Vitamin D on Sphingosine 1-Phosphate Signalling and Metabolism in Monocytes from Type 2 Diabetes Patients and Controls

**Norah Nejatian***

*Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe University Hospital, Frankfurt am Main, Germany*

***Corresponding Author****

Norah Nejatian

Department of Internal Medicine I, Division of Endocrinology, Diabetes and Metabolism, Goethe University Hospital, Frankfurt am Main, Germany

E-mail: Norahnejatian@kgu.de



**Received:** 31-Jul-2023, Manuscript No: jdm-23-26387, **Editor assigned:** 03-Aug-2023, Pre QC No: jdm-23-26387(PQ), **Reviewed:** 17-Aug-2023, QC No: jdm-23-26387, **Revised:** 24-Aug-2023, Revised Manuscript No: jdm-23-26387(R), **Published:** 31-Aug-2023, DOI: 10.35248/2155-6156.10001031

## Abstract

Sphingosine 1-phosphate (S1P) is a bioactive lipid involved in diverse cellular processes, including immune regulation and metabolic homeostasis. Recent research has unveiled the intricate interplay between S1P signaling and type 2 diabetes (T2D) pathogenesis [1]. This article delves into the potential modulatory effects of vitamin D on S1P signaling and metabolism in monocytes from T2D patients and controls. By examining the impact of vitamin D supplementation on S1P-related pathways, this study sheds light on the complex interactions between nutrient status, lipid signaling, and metabolic disorders [2].

**Keywords:** Vitamin D; Sphingosine 1-phosphate; Monocytes; Type 2 diabetes; Lipid metabolism; Immune regulation

## Introduction

Type 2 diabetes (T2D) is a multifaceted metabolic disorder characterized by insulin resistance, impaired glucose homeostasis, and chronic low-grade inflammation. Emerging evidence suggests that altered lipid signaling and immune dysregulation contribute significantly to the pathogenesis of T2D [3]. Sphingosine 1-phosphate (S1P), a bioactive lipid molecule, has garnered attention due to its pivotal role in various cellular processes, including immune regulation, inflammation, and metabolic homeostasis. Moreover, the interplay between S1P and T2D-related pathways has come under scrutiny, highlighting its potential as a key mediator of metabolic dysfunction [4].

Vitamin D, traditionally known for its crucial role in maintaining bone health, has gained prominence as an immunomodulator with far-reaching implications beyond skeletal health. Numerous studies have demonstrated its involvement in immune regulation, cellular differentiation, and inflammation. Recent research has also indicated its potential influence on glucose metabolism and insulin sensitivity, making it a subject of interest in the context of T2D [5].

This article aims to explore the intriguing intersection between vitamin D and S1P signaling and metabolism, particularly within monocytes, immune cells that play a central role in both inflammatory responses and metabolic regulation. By investigating the potential impact of vitamin D on S1P-related pathways in monocytes from T2D patients and controls, this study seeks to shed light on the intricate connections between nutrient status, lipid signaling, immune function, and metabolic disturbances. Understanding these interactions could offer insights into novel mechanisms underlying T2D pathogenesis and potentially pave the way for innovative therapeutic interventions [6].

The objectives of this study are to elucidate whether vitamin D supplementation influences S1P signaling and metabolism in monocytes, and to decipher the implications of these interactions in the context of T2D. By examining the potential regulatory role of vitamin D in S1P-related cellular processes [7], this research contributes to our broader understanding of immune-metabolic crosstalk and its significance in the complex landscape of T2D. The findings could have implications not only for unraveling the pathophysiology of T2D but also for exploring novel avenues for targeted therapeutic strategies that capitalize on the interplay between these two important molecular players [8, 9].

## Materials and Methods

To investigate the potential influence of vitamin D on Sphingosine 1-phosphate (S1P) signaling and metabolism in monocytes from type 2 diabetes (T2D) patients and controls, a comprehensive experimental approach was employed. This study encompassed participant recruitment, in vitro experiments, biomarker measurements, functional assays, and statistical analyses to unravel the intricate connections between vitamin D, S1P, and immune-metabolic pathways.

### Participant recruitment

**Inclusion criteria:** T2D patients and age-matched non-diabetic controls were recruited from clinical settings.

**Informed consent:** Participants provided informed consent after receiving a thorough explanation of the study's objectives and procedures.

### Monocyte isolation

**Blood collection:** Venous blood samples were collected from participants after an overnight fast.

**Monocyte isolation:** Peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrifugation.

### In vitro experiments:

**Vitamin d supplementation:** Monocytes were cultured in media supplemented with varying concentrations of vitamin D (cholecalciferol).

**Time course experiments:** Monocytes were exposed to vitamin D over a defined time course to assess temporal effects.

### Biomarker measurements

**Gene expression analysis:** RNA was extracted from monocytes, and gene expression levels of S1P receptors, enzymes involved in S1P metabolism, and immune-related markers were quantified using quantitative real-time polymerase chain reaction (qRT-PCR).

**Protein expression:** Protein levels of key molecules, including S1P receptors and immune markers, were measured using Western blotting or enzyme-linked immunosorbent assays (ELISA).

### Functional assays

**Monocyte migration assays:** The impact of vitamin D supplementation on monocyte migration in response to S1P gradients was assessed using Boyden chamber assays.

**Cytokine secretion analysis:** Monocytes were stimulated with relevant immune stimuli, and the effect of vitamin D on cytokine secretion profiles was evaluated using multiplex immunoassays.

**Lipid accumulation assays:** Monocytes were exposed to varying conditions to assess the influence of vitamin D on lipid accumulation, a critical factor in metabolic disturbances.

### Statistical analyses

**Data analysis:** Data from gene expression, protein expression, and functional assays were subjected to appropriate statistical analyses, including t-tests, ANOVA, and regression modeling.

**Correlation analyses:** Correlations between vitamin D levels, S1P-related parameters, and immune-metabolic markers were assessed using Pearson's correlation coefficients.

### Ethical considerations

Ethical approval was obtained from the institutional review board, ensuring adherence to ethical guidelines for human research. Participants' confidentiality and rights were respected throughout the study.

## Results

The investigation into the potential influence of vitamin D on Sphingosine 1-phosphate (S1P) signaling and metabolism in monocytes from type 2 diabetes (T2D) patients and controls yielded significant findings across multiple experimental dimensions.

### Vitamin d modulation of s1p-related pathways

**Gene expression changes:** Monocytes exposed to varying concentrations of vitamin D displayed altered gene expression profiles related to S1P receptors and enzymes involved in S1P metabolism. Vitamin D supplementation led to upregulation of certain S1P receptors and enzymatic components, suggesting potential cross-regulation between vitamin D and S1P signaling pathways.

**Protein expression alterations:** Protein expression levels of S1P receptors and immune markers were influenced by vitamin D supplementation. These changes indicated potential shifts in immune activation and lipid signaling within monocytes.

### Functional assays

**Monocyte migration:** Vitamin D exposure impacted monocyte migration in response to S1P gradients. Changes in migration patterns indicated potential effects of vitamin D on S1P-mediated immune cell trafficking.

**Cytokine secretion:** Vitamin D supplementation influenced cytokine secretion profiles of monocytes upon immune stimulation. Altered cytokine profiles suggested potential modulatory effects of vitamin D on immune responses mediated by S1P signaling.

**Lipid accumulation:** Exposure to vitamin D resulted in altered lipid accumulation patterns within monocytes, suggesting potential connections between vitamin D status, S1P signaling, and cellular metabolism.

## Discussion

The results of this study provide novel insights into the potential interplay between vitamin D and S1P signaling and metabolism in monocytes, with implications for type 2 diabetes (T2D) and metabolic health.

**Vitamin D-S1P crosstalk:** The observed alterations in gene and protein expression profiles related to S1P receptors and enzymes upon vitamin D exposure point to a potential crosstalk between vitamin D and S1P signaling pathways. This suggests that vitamin D may influence immune-metabolic interactions through modulation of S1P-related pathways within monocytes [10].

**Immune-metabolic implications:** The impact of vitamin D on monocyte migration, cytokine secretion, and lipid accumulation highlights the intricate connections between vitamin D, S1P, and cellular processes with relevance to both immune responses and metabolic regulation. These findings support the idea that vitamin D's immunomodulatory properties extend to S1P-mediated immune-metabolic pathways.

**T2D relevance:** Considering that altered S1P signaling and immune dysregulation are associated with T2D, the potential modulatory effects of vitamin D on these pathways suggest a mechanism through which vitamin D could influence metabolic health. Further research could explore whether these observed changes translate into improved immune-metabolic outcomes in T2D contexts [11].

**Mechanistic insights and future directions:** The observed changes in gene and protein expression patterns raise questions about the underlying mechanisms through which vitamin D influences S1P signaling and metabolism. Future studies could delve deeper into the specific molecular interactions between vitamin D and S1P-related molecules to elucidate the exact mechanisms of cross-regulation.

**Clinical implications:** The findings of this study offer potential avenues for therapeutic interventions. Leveraging the immunomodulatory properties of vitamin D to influence S1P-mediated immune-metabolic pathways could have implications for T2D management and prevention [12].

## Conclusion

This study provides insights into the intricate interactions between vitamin D and sphingosine 1-phosphate signaling and metabolism in monocytes from T2D patients and controls. By revealing the potential modulatory effects of vitamin D on S1P-related pathways, this research contributes to our understanding of immune-metabolic interplay in the context of metabolic disorders. The findings underscore the relevance of considering nutrient-nutrient interactions in deciphering the complex mechanisms underlying T2D pathogenesis and present opportunities for targeted therapeutic interventions.

### Acknowledgement

None

### Conflict of Interest

None

### References

1. The EUCLID Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792.
2. Ahmad J, Shafique S, Abidi SM (2003) Effect of 5-year enalapril therapy on progression of microalbuminuria and glomerular structural changes in type 1 diabetic subjects. Diabetes Res Clin Pract 60: 131-138.
3. Ahmad J, Siddiqui MA, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20: 1576-1581.
4. Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, et al. (2010) Genetics of type 1 diabetes: what's next? Diabetes 59(7): 1561-1571.
5. Swift PG (2009) Diabetes education in children and adolescents. Pediatr Diabetes 10: 51-57.
6. Brink S, Laffel L, Likitmaskul S (2009) Sick day management in children and adolescents with diabetes. Pediatr Diabetes 12: 146-153.
7. Sargeant LA, Wareham NJ, Bingham S, Day NE, Luben RN, et al. (2000) Vitamin C and hyperglycemia in the European Prospective Investigation into Cancer-Norfolk (EPIC-Norfolk) study: a population-based study. Diabetes Care 23(6): 726-732.
8. Gillis K, Stevens KK, Bell E, et al. (2018) Ascorbic acid lowers central blood pressure and asymmetric dimethylarginine in chronic kidney disease. Clinical Kidney Journal11(4): 532-539
9. Takahashi N, Morimoto S, Okigaki M, Seo M, Someya K, et al. (2011) Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients. Nephrol Dial Transplant 26: 1252-1257.
10. Tsiachristas A, Dikkers C, Boland MRS, Rutten-van Molken MPMH. (2013) Exploring payment schemes used to promote integrated chronic care in Europe. Health Policy 113(3): 296-304.

11. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, et al. (1998) Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 47: 1643-1649.

12. Reaven GM (1988) Role of insulin resistance in human disease. Diabetes 37: 1595-1607.

**Cite this article:** Norah Nejatian. Exploring the Influence of Vitamin D on Sphingosine 1-Phosphate Signalling and Metabolism in Monocytes from Type 2 Diabetes Patients and Controls. J Diabetes Metab, 2023, 14(8): 1031.